DAX+1,48 % EUR/USD+0,33 % Gold+0,26 % Öl (Brent)+1,12 %

AusCann !!! (Seite 2)


ISIN: AU000000AC89 | WKN: A2DLBP | Symbol: ACNNF
0,463
$
17:07:53
Nasdaq OTC
+0,54 %
+0,003 USD

Neuigkeiten zur AusCann Group Holdings Aktie

ZeitTitel
05.12.18

21.06.18


Beitrag schreiben

Begriffe und/oder Benutzer

 

Auf Wunsch von Auscann. Die haben irgend was wichtiges bekannt zu geben...
usCann Group Holdings Ltd (ASX:AC8) has been granted a trading halt by the ASX pending the release of information regarding a capital raising.

Shares in the company will remain halted until the earlier of the release of the relevant information or the commencement of trading on Thursday.

READ: AusCann Group Holdings to accelerate medical cannabis strategy through master grower appointment

Last week AusCann outlined that it intended to accelerate its Australian medical cannabis manufacturing operation through the appointment of Canadian Luke Pigeau as master grower.

Pigeau, who was appointed following an extensive global search, will oversee AusCann’s Tasmanian Alkaloids cultivation operation in Tasmania.

The appointment is complemented by the company entering into a research and development agreement with Canadian group Jade Cannabis.
SX-listed medical cannabis firm AusCann Group Holdings Ltd has successfully completed the placement of 30.4 million shares that netted the company A$33.4 million ($25 million) in fresh capital. In a disclosure to the Australia Securities Exchange, AusCann said the placement was made to investors from North America and Australia, including AusCann’s major shareholder, Canopy Growth Corporation, which, following completion of the placement, will increase its ownership to 11.2 per cent. The placement represents 30.4 million new fully paid ordinary shares in AusCann under an issue price of A$1.10, an 11.7 per cent discount on the weighted average price of its shares over the 15-day prior period of trade. Based in Australia, AusCann seeks to produce clinically validated cannabinoid medicines. It initially targets medications for neuropathic and chronic pain in Australia and Chile, while exploring global export opportunities.

Read more at: https://www.dealstreetasia.com/stories/auscann-cannabis-placement-101285/
Antwort auf Beitrag Nr.: 58.222.329 von Hyper-Hyper am 16.07.18 11:24:15Das Resultat sieht man eindeutig am Aktienkurs.


Beitrag zu dieser Diskussion schreiben